

This announcement is not an offer to purchase, a solicitation of an offer to purchase, an offer to sell, or a solicitation of an offer to sell the FCC Bonds. This announcement does not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law. This announcement is not for release, publication or distribution in or into, or to any person resident and/or located in, any jurisdiction where such release, publication or distribution is unlawful.

This announcement does not constitute an offer to sell or the solicitation of an offer to purchase any securities in the United States, India or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus which will contain detailed information about the Company and its management, as well as its financial statements. No public offering of securities is to be made by the Company in the United States.

8 April 2022

To, Dy. General Manager Department of Corporate Services, BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai – 400 001	To, The Manager – Listing National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
Ref: Scrip Code: 532296	Ref: Scrip Name: GLENMARK

Dear Sirs,

Re: Notice of Early Redemption by Glenmark Pharmaceuticals Limited (the “Company”) to the holders of its U.S.\$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022 (“Bonds”).

The Company had issued the Bonds in 2016 which are currently listed on the Singapore Exchange Securities Trading Limited. This is in furtherance of our earlier intimation letter dated 4 April, 2022. Pursuant to, and in accordance with, the terms of the trust deed dated 28 June 2016 (the “Trust Deed”) constituting the Bonds, the Company has elected to redeem and will redeem the Notes in full on 9 May 2022 (the “Redemption Date”) at the Early Redemption Amount pursuant to Condition 8.2 (Redemption at the option of the Issuer) of the terms and conditions of the Bonds.

The Early Redemption Amount is US\$ 942,860.24 plus interest accrued but unpaid to the Redemption Date. The Bonds will be cancelled as of the Redemption Date and interest will cease to accrue on and after the Redemption Date.

Upon the redemption and cancellation of the Bonds, the Bonds will be delisted from the Singapore Exchange Securities Trading Limited.

Capitalized terms used and not otherwise defined herein shall have the meaning given to them in the Trust Deed.



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

This announcement is for informational purposes only and shall not constitute an offer to purchase the Bonds.

We request you to take this on record, and to treat the same as compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary and Compliance Officer

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)